GovChime
Notice ID: adbfd5c9baa54229bed3ce681bad5e06Combined Synopsis/Solicitation

6505--Radiopharmaceuticals Base Plus 4 Option Years

Archived on April 8, 2024. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
4:00 PM UTC−05:00
Posted
March 28, 2024
Notice type
Combined Synopsis/Solicitation
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Veterans Affairs

Notice details

Office
245-NETWORK CONTRACT OFFICE 5 (36C245)
Place of performance
Beckley WV VA Medical Center 200 Veterans Ave. Beckley, WV. 25801
Last updated
Dec 6, 2025

Identifiers

Solicitation number
36C24524Q0181
Notice ID
adbfd5c9baa54229bed3ce681bad5e06

Description

RFQ 36C24524Q0181 - Amendment #1 Questions and Answers: NaTc04 in the statement of work as well as line item # 0003 is in the mCi amount, which can be equivalent to a multidose product. Yes, that is correct. Please provide pricing as it is historically. Line item 1007 is listed as a Unit Dose. The price difference is significant between the 2 unit of measures, and I was hoping you could clarify which Unit of measure we should use in our pricing. Please quote the pricing in millicuries. It was noted that Macroaggregated Albumin (Tc-MAA) used in Lung Perfusion studies was not listed on the request for quote. We do not need MAA for lung studies at this time. The solicitation references an Excel sheet that I don t see attached. Is there a specific one you would like us to use? You can choose to provide the CLINS in your own excel sheet or with the solicitation provided. It was questioned if needing Myoview, which is in the product list was accurate. Myoview will remain on the list, as we would like to have this in stock.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:36C24524Q0181
  1. Combined Synopsis
  1. 4×
    Combined SynopsisCurrentJan 19, 2024

    6505--Radiopharmaceuticals Base Plus 4 Option Years

    Notice adbfd5c9baa54229bed3ce681bad5e06 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
-Pre-Solicitation11/11/2026
The Defense Health Agency (DHA) Contracting Activity (DHACA), on behalf of the DHA’s Portfolio Acquisition Executive Medical Products (PAE MP), intends to issue a firm-fixed price Indefinite Delivery/Indefinite Quantity contract on a sole source basis under the authority of the Revolutionary Federal Acquisition Regulation (FAR) Overhaul, FAR 6.103-1, only one responsible source and no other supplies or services will satisfy agency requirements, to Vascular Solutions LLC, 6420 Sycamore Ct N, Maple Grove, Minnesota 55369-6032. Vascular Solutions, LLC is the only source able to meet the Government’s requirements. The Government has a has a critical requirement for supply of a Food and Drug Administration (FDA) approved Freeze Dried Plasma (FDP) product for transfusion when plasma is required and other plasma products are not available. The FDA approved Vascular Solutions, LLC FDP product, EZPLAZ™, on 29 July 2026. Vascular Solutions LLC holds the first and only FDA-approved (licensed) FPD product on the market. This Notice of Intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Responses must be supported with clear and convincing evidence articulating the ability to provide FDA approved FDP product. Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. If no written responses are received by the date listed below, an Indefinite Delivery/Indefinite Quantity contract will be awarded without further remark. Capability statements are due by 3:00 PM local time, 16 September 2026. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: timothy.j.kelly169.civ@health.mil and shannon.p.lertora.civ@health.mil.
-Special Notice09/16/2026
-AwardedOpen
Page 2 of 2 Page 2 of 2 PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue a Request for Proposal (RFP) 36E79727R0004 for an unrestricted procurement for Pantoprazole NA Tablets for the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have a unique NDC number. Glass bottles are not acceptable. Solicitation # 36E79727R0004 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about 12/22/2026 with a tentative closing date of 01/05/2027. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: http://www.sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Amber Zavala. Questions can be e-mailed to: amber.zavala@va.gov. The estimated annual requirements are as follows: Description Size Estimated Annual Requirements PANTOPRAZOLE NA 20MG TAB 90/BT 244,641 PANTOPRAZOLE NA 20MG TAB 500/BT 28,376 OR PANTOPRAZOLE NA 20MG TAB 1000/BT 14,188 PANTOPRAZOLE NA 40MG TAB 90/BT 965,273 PANTOPRAZOLE NA 40MG TAB 500/BT 237,162 OR PANTOPRAZOLE NA 40MG TAB 1000/BT 118,581
-Pre-Solicitation12/31/2026
Emergency Pharmacy Order of DigiFAB
-Sole Source / J&AOpen

Additional Details

Solicitation Number

36C24524Q0181

Archive Date

Apr 8, 2024

Office Address

LINTHICUM, MD, 21090